Molecular Cancer Therapeutics

A Journal of the American Association for Cancer Research

Volume 3, Number 7 **July 2004**

Articles

contents continued

Minireview

On the Cover



Targeting dependent cell surface activation of local thrombosis by a specific tumor vascular thrombogen (STVT). The *top panels* illustrate the ternary complex of the thrombogenic initiation complex TF/FVIIa/FXa (*left*) and STVT/FVIIa/FXa (*right*) on a cell surface. The TF, FVIIa, and FX are *blue, red,* and *yellow,* respectively. The STVT contains a targeting domain (*blue arrow*) fused with the soluble extracellular domain of TF. The TF domain assembles and provides the required cofactor function for the enzyme FVIIa and for presentation of the substrate FX. Only when properly docked on a supportive anionic plasmalemma microdomain will the construct regain function and initiate the thrombogenic cascade. The *lower panel* is a 3D model of Fn-TF3-218 associated with VIIa docked on a supportive cell surface. The fibronectin domain is *orange,* the TF extracellular domain is *yellow,* and the VIIa is *white*. The cell membrane is *blue* and the catalytic site amino acids of VIIa are highlighted in *red*. For details, see Liu et al. in this issue.

Molecular Cancer Therapeutics is abstracted or indexed in Chemical Abstracts, Index Medicus, MEDLINE, BIOSIS Previews, and Current Contents. *Molecular Cancer Therapeutics* is also published online. Please visit http://mct.aacrjournals.org.